Linked Life Data

19174037

Source:http://linkedlifedata.com/resource/pubmed/id/19174037

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-1-28
pubmed:abstractText
In haematological malignancies, molecular markers like fusion DNA from balanced translocations, point mutations, or over-expressed genes can now be used not only for diagnosis, but also for determination of the minimal residual disease (MRD) after cytoreduction with a sensitivity by far exceeding that of previous methodologies. The sensitivity of quantitative polymerase chain reaction typically reaches a validated identification of 1 malignant cell in 100,000.
pubmed:language
dan
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1603-6824
pubmed:author
pubmed:issnType
Electronic
pubmed:day
19
pubmed:volume
171
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
229-31
pubmed:dateRevised
2009-2-11
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
pubmed:affiliation
Immunhaematologisk Laboratorium, Haematologisk Afdeling R, Arhus Universitetshospital, Arhus Sygehus, DK-8000 Arhus C. phokland@ki.au.dk
pubmed:publicationType
Journal Article, English Abstract